Ovid Therapeutics (OVID) closed at $2.40 on November 16, 2026, down 5.5% from the previous close, on volume of 2,675,976 shares (30-day average 2,132,161).
Data as of November 16, 2026.
Guggenheim Keeps Their Buy Rating on Ovid Therapeutics (OVID)
TipRanks (Mon, 16-Nov 8:17 AM ET)
TipRanks (Thu, 12-Nov 6:01 AM ET)
Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 5-Nov 8:00 AM ET)
PRNewswire (Thu, 15-Oct 7:30 AM ET)
Ovid Therapeutics Secures $60 Million to Advance OV329 in Tuberous Sclerosis and Infantile Spasms
Market Chameleon (Wed, 18-Mar 6:30 AM ET)
Market Chameleon (Fri, 3-Oct 6:39 AM ET)
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Ovid Therapeutics trades on the NASDAQ stock market under the symbol OVID.
As of November 17, 2026, OVID stock price declined to $2.26 with 1,373,712 million shares trading.
OVID has a beta of 0.94, meaning it tends to be less sensitive to market movements. OVID has a correlation of 0.03 to the broad based SPY ETF.
OVID has a market cap of $426.53 million. This is considered a Small Cap stock.
Last quarter Ovid Therapeutics reported $0 in Revenue and -$.10 earnings per share. This fell short of revenue expectation by $-35,048 and missed earnings estimates by -$.02.
In the last 3 years, OVID traded as high as $4.10 and as low as $.24.
The top ETF exchange traded funds that OVID belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
OVID has outperformed the market in the last year with a return of +73.2%, while the SPY ETF gained +9.9%. However, in the most recent history, OVID shares have underperformed the stock market with its stock returning -20.1% in the last 3 month period and -5.4% for the last 2 week period, while SPY has returned -5.6% and -2.8%, respectively.
OVID support price is $2.25 and resistance is $2.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OVID shares will trade within this expected range on the day.